

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medlive Technology Co., Ltd.

醫脈通科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2192)

**UPDATE ON THE QUALIFICATIONS OF COMPANY SECRETARY
AND
RESIGNATION OF JOINT COMPANY SECRETARY
AND
CHANGE OF AUTHORISED REPRESENTATIVE**

Reference is made to the announcement of Medlive Technology Co., Ltd. (the “**Company**”) dated 12 June 2023 in relation to, among other things, the appointment of Ms. Chu Cheuk Ting (“**Ms. Chu**”) as a joint company secretary of the Company, an authorized representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) (“**Authorized Representative**”) and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (“**Process Agent**”), with effect from 12 June 2023, as well as the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance from Rules 3.28 and 8.17 of the Listing Rules for a period from the effective date of appointment of Ms. Chu, i.e. 12 June 2023, to 14 July 2024 in relation to the eligibility of Ms. Yang Yanling (“**Ms. Yang**”) to act as a joint company secretary of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Stock Exchange has confirmed that Ms. Yang is qualified to act as the company secretary of the Company under Rule 3.28 of the Listing Rules. Accordingly, Ms. Yang will act as the sole company secretary and an Authorised Representative of the Company with effect from 15 July 2024. Ms. Chu has resigned as a joint company secretary and an Authorised Representative of the Company with effect from 15 July 2024. Ms. Chu will remain as the Process Agent. Ms. Chu has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

The Company would like to express its gratitude to Ms. Chu for her contribution to the Company during the term of her service.

By order of the Board
Medlive Technology Co., Ltd.
Tian Liping
Chairwoman and Chief Executive Officer

Hong Kong, 15 July 2024

As at the date of this announcement, the Board comprises Ms. Tian Liping, Mr. Tian Lixin, Mr. Tian Lijun and Ms. Zhou Xin as executive Directors; Mr. Eiji Tsuchiya and Mr. Kazutaka Kanairo as non-executive Directors; and Mr. Richard Yeh, Dr. Ma Jun and Ms. Wang Shan as independent non-executive Directors.